Urological cancer, Malmö
1 – 10 of 467
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence : The PET index
2023) In European Journal of Nuclear Medicine and Molecular Imaging(
- Contribution to journal › Article
-
Mark
Pancreatic Cancer Organoids : An Emerging Platform for Precision Medicine?
(
- Contribution to journal › Scientific review
-
Mark
Men's Perception of Being Invited for Prostate Cancer Testing and the Information About Its Pros and Cons—A Survey from Two Population-based Testing Programmes
(
- Contribution to journal › Article
-
Mark
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
(
- Contribution to journal › Article
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection
(
- Contribution to journal › Letter
-
Mark
Salvage radiotherapy after radical prostatectomy : functional outcomes in the LAPPRO trial after 8-year follow-up
(
- Contribution to journal › Article
-
Mark
The need for core outcome sets in renal cancer clinical effectiveness research
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Urosymphyseal fistula after pelvic radiotherapy in a tertial referral centre - a rare entity with significant comorbidity requiring multidisciplinary management
(
- Contribution to journal › Article
-
Mark
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
(
- Contribution to journal › Article